XCSport体育
About Henlius
Company Profile
XCSport体育:Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
XCSport体育:Products in R&D
Clinical Trial
Science & Technology
R&D Result
XCSport体育:Innovation Centre
Technology Platform
Quality Management
XCSport体育:Manufacturing
Collaborations
Investor Relations
Information Disclosure
Corporate Governance
XCSport体育:Financial Reports
XCSport体育:Stock Info
XCSport体育:IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
Multi-media
XCSport体育:Media Reports
Media Enquiry
Careers
Talent Philosophy
XCSport体育:Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
XCSport体育:Customer Message
Privacy
Legal Statement
XCSport体育:Compliance
EN
简体
EN
繁體
Home
XCSport体育:About Henlius
Company Profile
XCSport体育:Corporate Culture
Honor
XCSport体育:Board of Directors
XCSport体育:Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
XCSport体育:R&D Result
Innovation Centre
XCSport体育:Technology Platform
XCSport体育:Quality Management
XCSport体育:Manufacturing
XCSport体育:Collaborations
Investor Relations
Information Disclosure
Listing Documents
Announcement & Circulars
Corporate Governance
Financial Reports
Stock Info
XCSport体育:IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Event
Popular Science
Media Reports
XCSport体育:Media Enquiry
Careers
Talent Philosophy
XCSport体育:Staff Life
Training and Development
Job Opportunities
XCSport体育:Contact Us
XCSport体育:Contact Information
XCSport体育:Customer Message
Privacy
Legal Statement
Compliance
搜索
Be the most trusted biotech company
XCSport体育:Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
XCSport体育:Multi-media
Company
XCSport体育:Popular Science
XCSport体育:Highlights
Download
XCSport体育:Media Reports
XCSport体育:Media Enquiry
2025-12-24
First Chinese Patient Dosed for Phase 3 MRCT on ER+/HER2- Breast Cancer of HLX78
2025-12-20
Latest Results of Serplulimab in The Field of Pancreatic Cancer Released In APA/JPS/CAP/IAP 2024 Annual Meeting in Oral Presentation
2025-12-19
Palleon Pharmaceuticals and Henlius Collaborate to Advance Glycan Editing as a Treatment for Autoimmune Diseases
2025-12-17
Henlius Becomes Newest Member of Biosimilars Forum
2025-12-16
Latest Results of Serplulimab in The Neoadjuvant Treatment of ESCC Released In 2024 ESMO IO
2025-12-09
Latest Results of 5 Clinical Trials Released at ESMO Asia 2024
2025-12-04
Henlius Receives IND Approval from NMPA for a Phase 1b/2 Clinical Trial of Its Novel PD-L1-Targeting ADC HLX43
2025-12-04
Henlius Receives Approval form NMPA for a Phase 2 Clinical Trial of Its Novel Anti-HER2 mAb HLX22
2025-12-04
China NMPA Accepts Henlius' NDA for HLX11, an Pertuzumab Biosimilar Candidate
1
2
3
...
10